Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy argenx NV ADR stock

Learn how to easily invest in argenx NV ADR stock.

argenx NV ADR is a biotechnology business based in the US. argenx NV ADR shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. argenx NV ADR employs 650 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in argenx NV ADR

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARGX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

argenx NV ADR stock price (NASDAQ: ARGX)

Use our graph to track the performance of ARGX stocks over time.

argenx NV ADR shares at a glance

Information last updated 2022-06-24.
Latest market close$373.58
52-week range$249.50 - $365.81
50-day moving average $316.72
200-day moving average $304.94
Wall St. target price$390.74
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-11.53

Buy argenx NV ADR shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy argenx NV ADR stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

argenx NV ADR price performance over time

Historical closes compared with the close of $373.58 from 2022-06-29

1 week (2022-06-23) 2.48%
1 month (2022-05-27) 15.62%
3 months (2022-03-30) 19.17%
6 months (2021-12-30) 5.82%
1 year (2021-06-30) 24.08%
2 years (2020-06-30) 65.87%
3 years (2019-06-28) 163.86%
5 years (2017-06-30) 1,661.34%

argenx NV ADR financials

Revenue TTM $381.2 million
Gross profit TTM $-52,254,000
Return on assets TTM -8.77%
Return on equity TTM -19.4%
Profit margin -156.1%
Book value $49.05
Market capitalisation $19.8 billion

TTM: trailing 12 months

argenx NV ADR share dividends

We're not expecting argenx NV ADR to pay a dividend over the next 12 months.

argenx NV ADR share price volatility

Over the last 12 months, argenx NV ADR's shares have ranged in value from as little as $249.5 up to $365.81. A popular way to gauge a stock's volatility is its "beta".

ARGX.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx NV ADR's is 1.0263. This would suggest that argenx NV ADR's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

argenx NV ADR overview

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S. À. R.

Frequently asked questions

What percentage of argenx NV ADR is owned by insiders or institutions?
Currently 0.002% of argenx NV ADR shares are held by insiders and 62.878% by institutions.
How many people work for argenx NV ADR?
Latest data suggests 650 work at argenx NV ADR.
When does the fiscal year end for argenx NV ADR?
argenx NV ADR's fiscal year ends in December.
Where is argenx NV ADR based?
argenx NV ADR's address is: Willemstraat 5, Breda, Netherlands, 4811 AH
What is argenx NV ADR's ISIN number?
argenx NV ADR's international securities identification number is: US04016X1019
What is argenx NV ADR's CUSIP number?
argenx NV ADR's Committee on Uniform Securities Identification Procedures number is: 04016X101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site